Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Zymeworks Inc
ZYME | US
28.10
USD0.67
2.44%
ZYME | US
About Zymeworks Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
24/04/2026
Close
28.10
Open
27.51
High
28.30
Low
26.94
Zymeworks Inc. a clinical-stage biopharmaceutical company discovers develops and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include Zanidatamab a human epidermal growth factor receptor 2 (HER2) that is in Phase 1 Phase 2 and Phase 3 clinical trials for the treatment of biliary tract gastroesophageal adenocarcinomas breast colorectal and endometrial cancers; and zanidatamab zovodotin a HER2 -targeted antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology including immuno-oncology agents and other therapeutic areas. The company has strategic partnerships and collaborations with BeiGene Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co. Ltd.; Janssen Biotech Inc.; LEO Pharma A/S; Iconic Therapeutics Inc.; Merck Sharp & Dohme Research GmbH; and Atreca Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver Canada.
View LessZYME | US
Risk
35.2
Sharpe
2.25
Luna's Score
67/100
Recommendation
Buy
Luna says (ZYME | US)
What's Working
Positive Momentum
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Revenue Growth (> 10%)
Strong Sharpe Ratio (> 1.2)
What's not Working
High Short-term Volatility
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
40.0%1 month
35.2%3 months
39.8%6 months
62.1%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
2.36
Debt to equity
0.05
Debt to assets
0.04
Ent. to EBITDA
0.34
Ent. to rev.
10.32
PEG
-
Other Fundamentals
EBITDA
-115.55M
MarketCap
2.00B
MarketCap(USD)
2.00B
Div. yield
-
Op. margin
-133.03
Erngs. growth
-
Rev. growth
174.80
Ret. on equity
-26.32
Short ratio
5.53
Short perc.
6.47
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
3.05
Range1M
5.29
Range3M
6.95
Volumes: Market Activity
Rel. volume
0.88
Price X volume
13.73M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 0.34 | - | Cheaper |
| Ent. to Revenue | 10.32 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 2.36 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 39.84 | - | Lower Risk |
| Debt to Equity | 0.05 | -1.23 | Expensive |
| Debt to Assets | 0.04 | 0.25 | Cheaper |
| Market Cap | 2.00B | - | Emerging |
